News
-
-
PRESS RELEASE
DEFENCE INVESTIGATES THE APPLICATION OF THE ACCUM® HYDROGEL TECHNOLOGY TO DELIVER GLP-1 IN ORDER TO INCREASE THE TREATMENT EFFICACY OF DIABETES AND WEIGHT LOSS
Defence Therapeutics Inc. explores using Accum® Hydrogel technology to enhance GLP-1 treatment for diabetes & weight loss. GLP-1 drugs aim to tackle obesity & comorbidities, amid growing global health challenges -
-
PRESS RELEASE
DEFENCE THERAPEUTICS COLLABORATION AGREEMENT WITH ORANO TO DEVELOP THE NEXT GENERATION OF TARGETED RADIO-IMMUNOTHERAPY FOR CANCER ADVANCES
Defence Therapeutics collaborates with Orano to develop targeted radio-immunotherapy for cancer, aiming to advance treatment efficacy with novel technology -
-
PRESS RELEASE
DEFENCE THERAPEUTICS GRANTED CNRI-H FROM THE CANADIAN NUCLEAR LABORATORIES TO ACCELERATE THE DEVELOPMENT OF ITS RADIO-IMMUNO-CONJUGATES PROGRAM
Defence Therapeutics granted CNRI-H from the Canadian Nuclear Laboratories to accelerate the development of its radio-immuno-conjugates program -
-
PRESS RELEASE
DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE IN PATIENTS WITH MELANOMA
Defence Therapeutics Inc. receives Health Canada's No Objection Letter for Phase I trial of ACCUM-002 as anti-cancer drug in melanoma patients. The study aims to assess safety, tolerability, and efficacy of the drug -
-
